AR110777A1 - Ácidos indanilaminopirazinilciclopropancarboxílicos composiciones farmacéuticas y sus usos en el tratamiento de enfermedades mediadas por gpr40 - Google Patents
Ácidos indanilaminopirazinilciclopropancarboxílicos composiciones farmacéuticas y sus usos en el tratamiento de enfermedades mediadas por gpr40Info
- Publication number
- AR110777A1 AR110777A1 ARP180100172A ARP180100172A AR110777A1 AR 110777 A1 AR110777 A1 AR 110777A1 AR P180100172 A ARP180100172 A AR P180100172A AR P180100172 A ARP180100172 A AR P180100172A AR 110777 A1 AR110777 A1 AR 110777A1
- Authority
- AR
- Argentina
- Prior art keywords
- indanilaminopirazinilciclopropancarboxílicos
- gpr40
- treatment
- pharmaceutical compositions
- diseases mediated
- Prior art date
Links
- 102100026148 Free fatty acid receptor 1 Human genes 0.000 title 1
- 101000912510 Homo sapiens Free fatty acid receptor 1 Proteins 0.000 title 1
- 239000002253 acid Substances 0.000 title 1
- 150000007513 acids Chemical class 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17153381 | 2017-01-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR110777A1 true AR110777A1 (es) | 2019-05-02 |
Family
ID=57906574
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180100172A AR110777A1 (es) | 2017-01-26 | 2018-01-25 | Ácidos indanilaminopirazinilciclopropancarboxílicos composiciones farmacéuticas y sus usos en el tratamiento de enfermedades mediadas por gpr40 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10253004B2 (enExample) |
| EP (1) | EP3573965B1 (enExample) |
| JP (1) | JP6968181B2 (enExample) |
| CN (1) | CN110214135B (enExample) |
| AR (1) | AR110777A1 (enExample) |
| TW (1) | TW201840541A (enExample) |
| WO (1) | WO2018138026A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10793530B2 (en) * | 2017-01-26 | 2020-10-06 | Boehringer Ingelheim International Gmbh | Benzylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
| CN110198928B (zh) * | 2017-01-26 | 2023-08-29 | 勃林格殷格翰国际有限公司 | 苄氧基吡啶基环丙烷甲酸、其药物组合物和用途 |
| WO2018138030A1 (en) * | 2017-01-26 | 2018-08-02 | Boehringer Ingelheim International Gmbh | Benzyloxypyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
| BR102018007822A2 (pt) | 2017-04-20 | 2018-11-06 | Gilead Sciences, Inc. | composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição |
| CR20200347A (es) | 2018-02-13 | 2020-09-23 | Gilead Sciences Inc | Inhibidores pd-1/pd-l1 |
| TWI712412B (zh) | 2018-04-19 | 2020-12-11 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
| SG11202012425QA (en) | 2018-07-13 | 2021-01-28 | Gilead Sciences Inc | Pd-1/pd-l1 inhibitors |
| WO2020086556A1 (en) | 2018-10-24 | 2020-04-30 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| KR20220150270A (ko) | 2019-10-07 | 2022-11-10 | 칼리오페, 인크. | Gpr119 효능제 |
| TW202140440A (zh) | 2020-02-28 | 2021-11-01 | 美商克力歐普股份有限公司 | Gpr40激動劑 |
| WO2021236617A1 (en) | 2020-05-19 | 2021-11-25 | Kallyope, Inc. | Ampk activators |
| CN116390925A (zh) | 2020-06-26 | 2023-07-04 | 卡尔优普公司 | Ampk活化剂 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US628476A (en) | 1898-03-18 | 1899-07-11 | Joseph Howard Kirk | Junction of cycle, motor-car, or other frames, &c. |
| US7704995B2 (en) * | 2002-05-03 | 2010-04-27 | Exelixis, Inc. | Protein kinase modulators and methods of use |
| CA2505322A1 (en) | 2002-11-08 | 2004-05-21 | Takeda Pharmaceutical Company Limited | Receptor function regulator |
| DE102004017930A1 (de) | 2004-04-14 | 2005-11-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
| CN101111486A (zh) * | 2005-01-31 | 2008-01-23 | 默克公司 | 抗糖尿病二环化合物 |
| PE20061127A1 (es) | 2005-02-15 | 2006-10-21 | Glaxo Group Ltd | Derivados de propanosulfonamida que potencian el receptor de glutamato |
| EP1866278A1 (en) | 2005-03-28 | 2007-12-19 | Pfizer, Inc. | Substituted aryloxoethyl cyclopropanecarboxamide compounds as vr1 receptor antagonists |
| EP1924546A1 (en) | 2005-09-14 | 2008-05-28 | Amgen, Inc | Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders |
| WO2007104717A1 (en) | 2006-03-15 | 2007-09-20 | Neurosearch A/S | Quinazolinones and their use as potassium channels activators |
| KR20110027657A (ko) | 2008-06-25 | 2011-03-16 | 다이이찌 산쿄 가부시키가이샤 | 카르복실산 화합물 |
| WO2010051819A1 (en) | 2008-11-10 | 2010-05-14 | Neurosearch A/S | Novel 2,3-diamino-quinazolinone derivatives and their medical use |
| WO2011094890A1 (en) | 2010-02-02 | 2011-08-11 | Argusina Inc. | Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators |
| US20120077814A1 (en) * | 2010-09-10 | 2012-03-29 | Zhong Wang | Sulfonamide, sulfamate, and sulfamothioate derivatives |
| US8642585B2 (en) | 2012-03-26 | 2014-02-04 | Boehringer Ingelheim International Gmbh | Indanyloxydihydrobenzofuranylacetic acids |
| US8633182B2 (en) * | 2012-05-30 | 2014-01-21 | Boehringer Ingelheim International Gmbh | Indanyloxyphenylcyclopropanecarboxylic acids |
| EP3049396B1 (en) | 2013-09-26 | 2017-11-15 | Boehringer Ingelheim International GmbH | Process and intermediates for preparing indanyloxydihydrobenzofuranyl acetic acid derivatives as gpr40 agonists |
| EP3074375B1 (en) * | 2013-11-28 | 2018-04-04 | Boehringer Ingelheim International GmbH | New indanyloxyphenylcyclopropanecarboxylic acids |
| JP6816107B2 (ja) * | 2015-08-07 | 2021-01-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | インダニルアミノピリジルシクロプロパンカルボン酸、医薬組成物及びこれらの使用 |
| EP3347358B1 (en) * | 2015-09-09 | 2019-11-27 | Boehringer Ingelheim International GmbH | [{[2,3-dihydro-1h-inden-1-yl]amino}-2h,3h-furo[3,2-b]pyridin-3-yl]acetic acids, pharmaceutical compositions and uses thereof |
| US10919859B2 (en) * | 2017-01-26 | 2021-02-16 | Boehringer Ingelheim International Gmbh | Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
| WO2018138030A1 (en) * | 2017-01-26 | 2018-08-02 | Boehringer Ingelheim International Gmbh | Benzyloxypyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
| CN110198928B (zh) * | 2017-01-26 | 2023-08-29 | 勃林格殷格翰国际有限公司 | 苄氧基吡啶基环丙烷甲酸、其药物组合物和用途 |
| US10793530B2 (en) * | 2017-01-26 | 2020-10-06 | Boehringer Ingelheim International Gmbh | Benzylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
-
2018
- 2018-01-22 JP JP2019540033A patent/JP6968181B2/ja active Active
- 2018-01-22 EP EP18703219.8A patent/EP3573965B1/en active Active
- 2018-01-22 US US15/876,237 patent/US10253004B2/en active Active
- 2018-01-22 WO PCT/EP2018/051383 patent/WO2018138026A1/en not_active Ceased
- 2018-01-22 CN CN201880007924.0A patent/CN110214135B/zh active Active
- 2018-01-25 AR ARP180100172A patent/AR110777A1/es unknown
- 2018-01-25 TW TW107102700A patent/TW201840541A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201840541A (zh) | 2018-11-16 |
| JP6968181B2 (ja) | 2021-11-17 |
| US20180208560A1 (en) | 2018-07-26 |
| CN110214135A (zh) | 2019-09-06 |
| CN110214135B (zh) | 2023-02-21 |
| US10253004B2 (en) | 2019-04-09 |
| WO2018138026A1 (en) | 2018-08-02 |
| EP3573965B1 (en) | 2021-06-23 |
| JP2020505394A (ja) | 2020-02-20 |
| EP3573965A1 (en) | 2019-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR110777A1 (es) | Ácidos indanilaminopirazinilciclopropancarboxílicos composiciones farmacéuticas y sus usos en el tratamiento de enfermedades mediadas por gpr40 | |
| EP3448397A4 (en) | THERAPEUTIC INITIATION OF A BORN IMMUNE RESPONSE IN A TARGET TISSUE | |
| EP3397149A4 (en) | TISSUE CHARTING AND TREATMENT | |
| PL3717471T3 (pl) | Nowe związki i zawierające je kompozycje farmaceutyczne do leczenia chorób | |
| IL256266A (en) | Lipids and lipid nanoparticle formulations for delivery of nucleic acids | |
| DK3889145T3 (da) | 8-cyano-5-piperidino-quinoliner som TLR7/8-antagonister og anvendelser deraf til behandling af immunsygdomme | |
| IL251530B (en) | Use of cannabinoids in the treatment of degenerative skeletal muscle diseases | |
| EP3263132C0 (en) | COMPOSITION FOR THE TREATMENT OF DISEASES ASSOCIATED WITH IL-6 | |
| IL255509B (en) | Compounds as modulators of ccr2, pharmaceutical preparations containing them and their use in the treatment of diseases | |
| SI3346995T1 (sl) | Terapevtski sestavek za zdravljenje virusa človeške imunske pomanjkljivosti | |
| DK3658132T3 (da) | Sammensætninger omfattende aminosyrer til anvendelse ved behandling af mitokondrielle dysfunktion-relaterede sygdomme | |
| HRP20260171T1 (hr) | Peptidi za liječenje i prevenciju bolesti nealkoholne masne jetre | |
| PL3381451T3 (pl) | Kompozycja farmaceutyczna stosowana do redukcji zlokalizowanej tkanki tłuszczowej i zastosowanie kompozycji farmaceutycznej | |
| EP3329400A4 (en) | DISAMBING OF SEARCH QUESTIONS | |
| MX2018003700A (es) | Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de higado graso, y uso de los mismos. | |
| EP3355879A4 (en) | Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids | |
| EP3597208A4 (en) | PHARMACEUTICAL COMPOSITION CONTAINING ATPIF1 FOR THE TREATMENT OF DIABETES | |
| ZA201702385B (en) | Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states | |
| DK3108255T3 (da) | Fremgangsmåder og farmaceutiske sammensætninger til behandling af sygdomme medieret af nrp-1/obr-komplekssignalvejen | |
| PL3424499T3 (pl) | Kompozycja farmaceutyczna do leczenia bólu neuropatycznego | |
| EP3572095A4 (en) | Pharmaceutical composition used for treatment of htlv-1-associated myelopathy | |
| ITUA20162575A1 (it) | Composizione farmaceutica o nutraceutica per l’uso nel trattamento della sindrome dell’ovaio policistico o di malattie o disturbi correlati ad essa | |
| EP3542824A4 (en) | MOLECULE INDUCING THE DEGRADATION OF Ras PROTEINS AND PHARMACEUTICAL COMPOSITION | |
| BR112017024908A2 (pt) | usos terapêuticos da 4-cloroquinurenina | |
| EP3556402A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF HEPATITIS B |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |